

Product no **AS00 001****Anti-FVIIa | Coagulation factor VIIa (50 µg)****Product information****Immunogen** | Recombinant human Factor VIIa (NovoSeven®, Novo Nordisk A/S Denmark)**Host** | Rabbit**Clonality** | Polyclonal**Purity** | Immunogen affinity purified IgG in PBS pH 7.4.**Format** | Lyophilized**Quantity** | 50 µg**Reconstitution** | For reconstitution add 50 µl of sterile water**Storage** | Store lyophilized/reconstituted at -20°C; once reconstituted make aliquots to avoid repeated freeze-thaw cycles. Please remember to spin the tubes briefly prior to opening them, to avoid any losses that might occur from material adhering to the cap or sides of the tube.**Additional information** | No significant difference in binding to Factor VII and Factor VIIa.

Antibody is purified to total IgG fraction, followed by purification on specific FVIIa column.

Application information**Recommended dilution** | 1 : 15 000 (I-ELISA), 14 µg/ml (IL)**Expected | apparent MW** | 52 kDa (this is MW of Factor VIIa)**Confirmed reactivity** | Human**Predicted reactivity** | Primates**Not reactive in** | No confirmed exceptions from predicted reactivity are currently known**Additional information** | This antibody is purified using Protein G, to obtain a total IgG fraction**Selected references** | Lopez-Vilchez et al. (2009). Traffic of rFVIIa through Endothelial Cells and Redistribution into Subendothelium: Implications for a Prolonged Hemostatic Effect. Journal of Coagulation Disorders, October 1: (1). (immunolocalization)